Advertisement

Journal of Neuro-Oncology

, Volume 85, Issue 3, pp 241–244 | Cite as

No association of MDM2 SNP309 with risk of glioblastoma and prognosis

  • Soufiane El Hallani
  • Yannick Marie
  • Ahmed Idbaih
  • Mathieu Rodero
  • Blandine Boisselier
  • Florence Laigle-Donadey
  • François Ducray
  • Jean-Yves Delattre
  • Marc Sanson
Lab. Investigation-Human/Animal Tissue

Abstract

The MDM2 SNP309 variant has been shown to increase MDM2 expression and to be associated with tumor formation. In glioblastomas, the P53/MDM2 pathway is of crucial importance and MDM2 amplification is related to poor prognosis. However, we show here that MDM2 SNP309 is not associated with glioblastoma risk, and is not a prognostic factor.

Keywords

Glioblastoma MDM2 Polymorphism Prognosis 

Notes

Acknowledgements

Work supported by the Délégation à la Recherche Clinique (AP-HP; grant no MUL 03012).

References

  1. 1.
    Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY (2003) Primary brain tumours in adults. Lancet 361:323–331PubMedCrossRefGoogle Scholar
  2. 2.
    Sanson M, Thillet J, Hoang-Xuan K (2004) Molecular changes in gliomas. Curr Opin Oncol 16:607–613PubMedCrossRefGoogle Scholar
  3. 3.
    Houillier C, Lejeune J, Benouaich-Amiel A, Laigle-Donadey F, Criniere E, Mokhtari K, Thillet J, Delattre JY, Hoang-Xuan K, Sanson M (2006) Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 106:2218–2223PubMedCrossRefGoogle Scholar
  4. 4.
    Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591–602PubMedCrossRefGoogle Scholar
  5. 5.
    Walsh CS, Miller CW, Karlan BY, Koeffler HP (2007) Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol 104:660–664PubMedCrossRefGoogle Scholar
  6. 6.
    Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, Goto H (2006) MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 24:4434–4440PubMedCrossRefGoogle Scholar
  7. 7.
    Dharel N, Kato N, Muroyama R, Moriyama M, Shao RX, Kawabe T, Omata M (2006) MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res 12:4867–4871PubMedCrossRefGoogle Scholar
  8. 8.
    Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, Tan W, Liu Z, Lin D (2005) The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 65:9582–9587PubMedCrossRefGoogle Scholar
  9. 9.
    Onat OE, Tez M, Ozcelik T, Toruner GA (2006) MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res 26:3473–3475PubMedGoogle Scholar
  10. 10.
    Campbell IG, Eccles DM, Choong DY (2006) No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett 240:195–197PubMedCrossRefGoogle Scholar
  11. 11.
    Millikan RC, Heard K, Winkel S, Hill EJ, Heard K, Massa B, Mayes L, Williams P, Holston R, Conway K, Edmiston S, de Cotret AR (2006) No association between the MDM2-309 T/G promoter polymorphism and breast cancer in African-Americans or Whites. Cancer Epidemiol Biomarkers Prev 15:175–177PubMedCrossRefGoogle Scholar
  12. 12.
    Petenkaya A, Bozkurt B, Akilli-Ozturk O, Kaya HS, Gur-Dedeoglu B, Yulug IG (2006) Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk. Anticancer Res 26:4975–4977PubMedGoogle Scholar
  13. 13.
    Wilkening S, Bermejo JL, Burwinkel B, Klaes R, Bartram CR, Meindl A, Bugert P, Schmutzler RK, Wappenschmidt B, Untch M, Hemminki K, Forsti A (2006) The single nucleotide polymorphism IVS1 + 309 in mouse double minute 2 does not affect risk of familial breast cancer. Cancer Res 66:646–648PubMedCrossRefGoogle Scholar
  14. 14.
    Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, Jin G, Liu J, Wang X, Wei Q, Shen H (2006) Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett 240:261–267PubMedCrossRefGoogle Scholar
  15. 15.
    Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, Bono P, Arola J, Jarvinen HJ, Mecklin JP, Atula T, Kontio R, Makitie AA, Suominen S, Leivo I, Vahteristo P, Aaltonen LM, Aaltonen LA (2005) The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 42:694–698PubMedCrossRefGoogle Scholar
  16. 16.
    Pine SR, Mechanic LE, Bowman ED, Welsh JA, Chanock SC, Shields PG, Harris CC (2006) MDM2 SNP309 and SNP354 are not associated with lung cancer risk. Cancer Epidemiol Biomarkers Prev 15:1559–1561PubMedCrossRefGoogle Scholar
  17. 17.
    Hu Z, Ma H, Lu D, Qian J, Zhou J, Chen Y, Xu L, Wang X, Wei Q, Shen H (2006) Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int J Cancer 118:1275–1278PubMedCrossRefGoogle Scholar
  18. 18.
    Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen A (2006) Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 119:718–721PubMedCrossRefGoogle Scholar
  19. 19.
    Li G, Zhai X, Zhang Z, Chamberlain RM, Spitz MR, Wei Q (2006) MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. Carcinogenesis 27:2028–2033PubMedCrossRefGoogle Scholar
  20. 20.
    Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ (2006) MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66:5104–5110PubMedCrossRefGoogle Scholar
  21. 21.
    Galic V, Willner J, Wollan M, Garg R, Garcia R, Goff BA, Gray HJ, Swisher EM (2007) Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosomes Cancer 46:239–247PubMedCrossRefGoogle Scholar
  22. 22.
    Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, Belluco C, Montagna M, Agata S, D’Andrea E, Nitti D, Amadori A, Bertorelle R (2006) Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 98:285–288PubMedCrossRefGoogle Scholar
  23. 23.
    Wasielewski M, Nagel JH, Brekelmans C, Klijn JG, van den Ouweland A, Meijers-Heijboer H, Schutte M (2006) MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling. Breast Cancer Res TreatGoogle Scholar
  24. 24.
    Bond GL, Menin C, Bertorelle R, Alhopuro P, Aaltonen LA, Levine AJ (2006) MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet 43:950–952PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Soufiane El Hallani
    • 1
    • 2
  • Yannick Marie
    • 1
    • 2
  • Ahmed Idbaih
    • 1
    • 2
    • 3
  • Mathieu Rodero
    • 4
  • Blandine Boisselier
    • 1
    • 2
  • Florence Laigle-Donadey
    • 1
    • 2
  • François Ducray
    • 1
    • 2
    • 3
  • Jean-Yves Delattre
    • 1
    • 2
    • 3
  • Marc Sanson
    • 1
    • 2
    • 3
  1. 1.INSERM, U711, Biologie des Interactions Neurones & GlieParisFrance
  2. 2.Faculté de MédecineUniversité Pierre et Marie CurieParisFrance
  3. 3.AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie MazarinParisFrance
  4. 4.Laboratoire d’Immunologie CellulaireINSERM U543ParisFrance

Personalised recommendations